In contrast, increased expression of TRPV6 in prostate cancer cell lines LNCaP and PC-3 correlates with resistance to cisplatin and thapsigargin, hence TRPV6 inhibition enhances cytotoxic effect of these drugs [232]. This evidence concerns the gene TRPV6 and prostate carcinoma.